Journal of Experimental Therapeutics and Oncology, Vol. 8, pp. 203–210 Reprints available directly from the publisher Photocopying permitted by license only
© 2010 Old City Publishing, Inc. Published by license under the OCP Science imprint, a member of the Old City Publishing Group.
The differential expression of hCNT1 and hENT1 in breast cancer and the possible impact on breast cancer therapy Jane Lane1, Tracey A Martin1, Christopher McGuigan2, Malcolm D Mason1 and Wen G Jiang*,1
1
Schools of Medicine and 2Pharmacy, Cardiff University, Cardiff, Wales, United Kingdom
*Correspondence to: Professor Wen G Jiang Metastasis and Angiogenesis Research Group Cardiff School of Medicine, Cardiff University Heath Park, Cardiff CF14 4XN, U.K. Telephone: +44(0)2920742739; Fax: +44(0)2920742895. E-mail:
[email protected]
(Received January 26, 2010; accepted January 27, 2010; sponsored by: Dr. Richard J. Ablin)
hCNT1 and hENT1, two members of the human nucleoside transporter families, expression levels were investigated, in normal and in breast tumour tissues, together with effects of gemcitabine cytotoxicity and in vivo tumour growth in MDA-MB-231 cells. hCNT1 and hENT1 levels were lower in tumour samples than in normal background tissue (p
